NCT02663622View on ClinicalTrials.gov

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 19, 2016

Primary Completion Date

June 8, 2020

Study Completion Date

May 18, 2021

Conditions
Graft Versus Host DiseaseHematopoietic Stem Cell TransplantationLeukemia
Interventions
DRUG

Efprezimod alfa

Acute GVHD prophylaxis

DRUG

Methotrexate

Acute GVHD prophylaxis

DRUG

Tacrolimus

Acute GVHD prophylaxis

DRUG

Placebo

100 ml saline IV infusion.

Trial Locations (4)

43210

Ohio State University, Columbus

46202

Indiana University School of Medicine, Indianapolis

48109

The University of Michigan Comprehensive Cancer Center, Ann Arbor

48201

Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

Ohio State University

OTHER

collaborator

University of Michigan Rogel Cancer Center

OTHER

collaborator

Indiana University School of Medicine

OTHER

collaborator

Barbara Ann Karmanos Cancer Institute

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02663622 - Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) | Biotech Hunter | Biotech Hunter